Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 2/20 | 0.73 |
| ▸ | CA2 | P00918 | 2/20 | 0.73 |
| ▸ | CA9 | Q16790 | 2/20 | 0.73 |
| ▸ | CA12 | O43570 | 1/20 | 0.73 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.72 |
| ▸ | MAPT | P10636 | 1/20 | 0.69 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.66 |
| ▸ | MEN1 | O00255 | 3/20 | 0.64 |
| ▸ | GAA | P10253 | 1/20 | 0.64 |
| ▸ | POLB | P06746 | 2/20 | 0.63 |
| ▸ | ATM | Q13315 | 1/20 | 0.63 |
| ▸ | CA7 | P43166 | 1/20 | 0.62 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.62 |
| ▸ | LMNA | P02545 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10841849 | 0.91 | MTNR1A (0.62) | CA1CA2CA9CA12KMT2A | |
| SCHEMBL27439284 | 0.90 | CA12 (0.60) | CA1CA2CA9CA12KMT2A | |
| SCHEMBL7358841 | 0.88 | CA12 (0.69) | CA1CA2CA9CA12KMT2A | |
| SCHEMBL2224069 | 0.87 | CA12 (0.73) | CA1CA2CA9CA12KMT2A | |
| SCHEMBL901614 | 0.87 | CA12 (0.73) | CA1CA2CA9CA12KMT2A | |
| SCHEMBL7265002 | 0.87 | CA12 (0.73) | CA1CA2CA9CA12KMT2A | |
| SCHEMBL10359474 | 0.87 | CA12 (0.73) | CA1CA2CA9CA12KMT2A | |
| SCHEMBL25773443 | 0.87 | MTNR1A (0.69) | CA1CA2CA9CA12KMT2A | |
| SCHEMBL12635586 | 0.87 | CA12 (0.57) | CA1CA2CA9CA12KMT2A | |
| Water SCHEMBL11279885 | 0.86 | CA12 (0.71) | CA1CA2CA9CA12KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1379668-A | 3(5)-ureido-pyrazole derivatives, process for their preparation and their use as antitumor agents | PHARMACIA & UPJOHN SPA (IT) | 2002-11-13 | — | — | CN | claimed |
| WO-2026003867-A1 | AN IMPROVED PROCESS FOR THE PREPARATION OF ENSIFENTRINE AND ITS PURIFICATION THEREOF | NEULAND LABORATORIES LIMITED (IN) | 2026-01-02 | — | — | WO | disclosed |
| EP-4609864-A1 | PHARMACEUTICAL COMPOSITION CONTAINING ISOQUINOLINONE COMPOUND, AND PREPARATION METHOD THEREFOR | Jiangsu Hengrui Pharmaceuticals Co., Ltd. (CN) | 2025-09-03 | — | — | EP | disclosed |
| EP-4610257-A1 | CRYSTAL FORM OF ISOQUINOLINONE COMPOUND AND PREPARATION METHOD THEREFOR | Jiangsu Hengrui Pharmaceuticals Co., Ltd. (CN) | 2025-09-03 | — | — | EP | disclosed |
| CN-119923263-A | Pharmaceutical composition containing isoquinolinones and preparation method thereof | 江苏恒瑞医药股份有限公司 | 2025-05-02 | — | — | CN | disclosed |
| US-20240217974-A1 | ISOQUINOLONE COMPOUND AND USE THEREOF | JIANGSU HENGRUI PHARMACEUTICALS CO., LTD. (CN) | 2024-07-04 | — | — | US | disclosed |
| US-20240217974-A1 | ISOQUINOLONE COMPOUND AND USE THEREOF | JIANGSU HENGRUI PHARMACEUTICALS CO., LTD. (CN) | 2024-07-04 | — | — | US | disclosed |
| US-20240217974-A1 | ISOQUINOLONE COMPOUND AND USE THEREOF | JIANGSU HENGRUI PHARMACEUTICALS CO., LTD. (CN) | 2024-07-04 | — | — | US | disclosed |
| WO-2024088402-A1 | CRYSTAL FORM OF ISOQUINOLINONE COMPOUND AND PREPARATION METHOD THEREFOR | 江苏恒瑞医药股份有限公司 | 2024-05-02 | — | — | WO | disclosed |
| WO-2024088364-A1 | PHARMACEUTICAL COMPOSITION CONTAINING ISOQUINOLINONE COMPOUND, AND PREPARATION METHOD THEREFOR | 江苏恒瑞医药股份有限公司 | 2024-05-02 | — | — | WO | disclosed |
| CN-116917287-A | Isoquinolinones and use thereof | 苏州盛迪亚生物医药有限公司 | 2023-10-20 | — | — | CN | disclosed |
| WO-2023109802-A1 | TRICYCLIC FUSED HETEROCYCLIC PDE3/4 DUAL INHIBITOR AND USE THEREOF | 海思科医药集团股份有限公司 | 2023-06-22 | — | — | WO | disclosed |
| WO-2022228544-A1 | ISOQUINOLONE COMPOUND AND USE THEREOF | 苏州盛迪亚生物医药有限公司 | 2022-11-03 | — | — | WO | disclosed |
| US-6063789-A | Aminoisoquinolines and aminotheinopyridine derivatives and their use as anti-inflammatory agents | ASTRA PHARMACEUTICALS, LTD. (GB) | 2000-05-16 | — | — | US | disclosed |
| EP-0973773-A1 | PYRIMIDO-ISOQUINOLINE COMPOUNDS WITH ANTICONVULSIVE ACTION | SMITHKLINE BEECHAM PLC (GB) | 2000-01-26 | — | — | EP | disclosed |
| CN-1221407-A | Aminoisoquinolines and aminothienopyridine derivatives and their use as anti-inflammatory agents | ASTRA PHARMA PROD (GB) | 1999-06-30 | — | — | CN | disclosed |
| EP-0892784-A1 | AMINOISOQUINOLINES AND AMINOTHIENOPYRIDINE DERIVATIVES AND THEIR USE AS ANTI-INFLAMMATORY AGENTS | Astra Pharmaceuticals Limited (GB) | 1999-01-27 | — | — | EP | disclosed |
| WO-1998045293-A1 | PYRIMIDO-ISOQUINOLINE COMPOUNDS WITH ANTICONVULSIVE ACTION | SMITHKLINE BEECHAM PLC (GB) | 1998-10-15 | — | — | WO | disclosed |
| WO-1997038977-A1 | AMINOISOQUINOLINES AND AMINOTHIENOPYRIDINE DERIVATIVES AND THEIR USE AS ANTI-INFLAMMATORY AGENTS | ASTRA PHARMACEUTICALS LTD. (GB) | 1997-10-23 | — | — | WO | disclosed |
| US-4581172-A | Substituted pyrimido[6,1-a]isoquinolin-4-ones,pyrimido[6,1-a]benzozepin-4-ones and pyrimido[6,1-a]benzodiazepin-4-ones useful for prevention of thromboses and treating hypertension | HOFFMANN-LA ROCHE INC. (US) | 1986-04-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240217974-A1 | ISOQUINOLONE COMPOUND AND USE THEREOF | CYP4A11, CYP11B2, NQO1 | CA1 3724/4885CA2 2727/4885CA9 4336/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.